Cargando…
Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells
Poly(ADP-Ribose) (PAR) polymerase (PARP) inhibitors represent a promising class of novel anticancer agents. The present study explores the molecular rationale for combining veliparib (ABT-888) with camptothecin (CPT) and its clinical derivatives, topotecan and irinotecan. ABT-888 inhibited PAR induc...
Autores principales: | Zhang, Yong-Wei, Regairaz, Marie, Seiler, Jennifer A., Agama, Keli K., Doroshow, James H., Pommier, Yves |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089458/ https://www.ncbi.nlm.nih.gov/pubmed/21227924 http://dx.doi.org/10.1093/nar/gkq1304 |
Ejemplares similares
-
Poly(ADP-ribose) polymerases covalently modify strand break termini in DNA fragments in vitro
por: Talhaoui, Ibtissam, et al.
Publicado: (2016) -
Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
por: Ström, Cecilia E., et al.
Publicado: (2011) -
SLX4IP acts with SLX4 and XPF–ERCC1 to promote interstrand crosslink repair
por: Zhang, Huimin, et al.
Publicado: (2019) -
Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress
por: Gagné, Jean-Philippe, et al.
Publicado: (2012) -
Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
por: Clements, Kristen E, et al.
Publicado: (2018)